Granahan Investment Management Inc. MA Has $6.33 Million Position in Pacira Pharmaceuticals, Inc. (PCRX)

Granahan Investment Management Inc. MA increased its holdings in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 19.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 168,464 shares of the company’s stock after buying an additional 27,609 shares during the period. Granahan Investment Management Inc. MA owned 0.42% of Pacira Pharmaceuticals worth $6,326,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. bought a new position in Pacira Pharmaceuticals in the 2nd quarter worth approximately $114,000. Cubist Systematic Strategies LLC boosted its holdings in Pacira Pharmaceuticals by 121.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after buying an additional 1,752 shares during the period. QS Investors LLC bought a new position in Pacira Pharmaceuticals in the 2nd quarter worth approximately $157,000. Ameritas Investment Partners Inc. boosted its holdings in Pacira Pharmaceuticals by 9.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after buying an additional 302 shares during the period. Finally, Spectrum Management Group Inc. bought a new position in Pacira Pharmaceuticals in the 3rd quarter worth approximately $166,000.

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at $44.20 on Tuesday. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same period in the prior year, the company posted $0.20 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. equities research analysts expect that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current year.

Several research analysts recently commented on the stock. Mizuho reaffirmed a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Goldman Sachs Group assumed coverage on shares of Pacira Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $41.00 price objective for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $44.00 price objective (down from $48.00) on shares of Pacira Pharmaceuticals in a report on Sunday, October 1st. Needham & Company LLC reaffirmed a “buy” rating on shares of Pacira Pharmaceuticals in a report on Tuesday, September 26th. Finally, Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Tuesday, October 3rd. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $48.86.

In related news, Director Mark A. Kronenfeld acquired 1,000 shares of the stock in a transaction dated Friday, November 10th. The shares were purchased at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the transaction, the director now owns 6,795 shares in the company, valued at approximately $282,672. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Kristen Marie Williams sold 10,000 shares of the firm’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the chief accounting officer now owns 23,455 shares in the company, valued at approximately $938,200. The disclosure for this sale can be found here. Insiders sold a total of 69,735 shares of company stock worth $2,692,594 over the last quarter. Corporate insiders own 6.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Week Herald and is the property of of Week Herald. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://weekherald.com/2017/12/12/granahan-investment-management-inc-ma-has-6-33-million-position-in-pacira-pharmaceuticals-inc-pcrx.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply